EUVIMEDEUVIMED entdecken
Crossref

Dual‐Targeting BCMA – CD19 CAR ‐T Cell Therapy in Systemic Lupus Erythematosus: Single‐Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution

Zhenghao He, Weijia Wang, Qianwen Li, Shihao Ding, Mingxia Wang, Ming Hong iD

Arthritis & Rheumatology · 2026-10 · 78 (10) · 2110-2123

DOI: 10.1002/art.70117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 02.04.2026. Verfasst von Zhenghao He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Zhongshan People's Hospital, Zhongshan, Guangdong, People's Republic of China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antigens, CD19, B-Cell Maturation Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Medical Science Research Foundation of Guangdong Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate peripheral immune reconstitution following BCMA–CD19 dual‐targeting CAR‐T therapy in patients with systemic lupus erythematosus (SLE).

Methods

Single‐cell RNA sequencing and parallel B cell receptor (BCR) and T cell receptor sequencing were performed on peripheral blood mononuclear cells from five patients with SLE before infusion and after peripheral B cell reconstitution (median 90 days postinfusion). These data were integrated with public datasets from seven patients with SLE treated with CD19 single‐targeting CAR‐T and three healthy controls for comparative analysis (total N = 15 subjects; 176,182 single cells analyzed).

Results

Dual‐targeting CAR‐T induced marked depletion of B‐lineage populations, including plasma‐lineage clusters that persisted after CD19 therapy. Specifically, cluster 2 decreased from 10.70% to 2.67% and cluster 3 from 9.55% to 3.12% in the dual‐targeting cohort, whereas cluster 3 increased (6.78%–12.19%) in the single‐targeting comparator. In B cells, dual targeting produced greater suppression of RIG‐I/MDA5 and type I interferon transcriptional programs than single‐targeting therapy. BCR repertoires shifted toward an IGHM‐dominant (49.83%–89.19%, P < 0.05), naïve‐biased profile, with contraction of pre‐enriched class‐switched clones and restoration of diversity toward healthy‐like profiles. Clinical improvement was significant (mean SLE Disease Activity Index decreased from 9.6 to 2.4, P < 0.05), paralleling these molecular changes.

Conclusion

BCMA–CD19 dual CAR‐T therapy was associated with deeper depletion of plasma‐lineage compartments and a tendency toward more pronounced reversal of SLE‐associated molecular signatures. This exploratory finding suggests a potential advantage of dual targeting in achieving a more comprehensive humoral reset in SLE, which warrants further direct comparative studies to determine clinical superiority. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntigens, CD19B-Cell Maturation AntigenImmunotherapy, AdoptiveB-LymphocytesImmune ReconstitutionHumansFemaleAdultSingle-Cell AnalysisMaleMiddle AgedReceptors, Antigen, B-CellReceptors, Chimeric Antigen

Substanzen

Antigens, CD19B-Cell Maturation AntigenTNFRSF17 protein, humanReceptors, Antigen, B-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Plastic Surgery, Zhongshan People's Hospital, Zhongshan, Guangdong, People's Republic of China.
  • Department of Dermatology, Second Xiangya Hospital, Hunan Key Laboratory of Medical Epigenomics, Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Central South University, Chang…
  • Institute of Advanced Diagnostic and Clinical Medicine, Zhongshan People's Hospital, Zhongshan, Guangdong, People's Republic of China.
  • Department of Rheumatology and Immunology, Zhongshan People's Hospital, Zhongshan, Guangdong, People's Republic of China.

ORCID-Profile: Ming Hong

Förderung

  • Medical Science Research Foundation of Guangdong Province of China

Zitieren

APA

He, Z., Wang, W., Li, Q., Ding, S., Wang, M., & Hong, M. (2026). Dual‐Targeting BCMA – CD19 CAR ‐T Cell Therapy in Systemic Lupus Erythematosus: Single‐Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution. Arthritis & Rheumatology, 78(10), 2110-2123. https://doi.org/10.1002/art.70117

Vancouver

He Z, Wang W, Li Q, Ding S, Wang M, Hong M. Dual‐Targeting BCMA – CD19 CAR ‐T Cell Therapy in Systemic Lupus Erythematosus: Single‐Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution. Arthritis & Rheumatology. 2026;78(10):2110-2123. doi:10.1002/art.70117

BibTeX
@article{He2026,
  author = {He, Zhenghao and Wang, Weijia and Li, Qianwen and Ding, Shihao and Wang, Mingxia and Hong, Ming},
  title = {Dual‐Targeting BCMA – CD19 CAR ‐T Cell Therapy in Systemic Lupus Erythematosus: Single‐Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  volume = {78},
  number = {10},
  pages = {2110--2123},
  doi = {10.1002/art.70117}
}
Kostenlos starten →